SecBot SecBot

VRTX

VERTEX PHARMACEUTICALS INC
Nasdaq· Pharmaceutical Preparations· Inc. MA· CIK 0000875320 Biotech & Drug Discovery
$533.18 −4.61 (−0.86%)
Nov 17 4:00 PM ET · prev $537.79
Market cap
$136.6B
Large cap
Consensus
Buy
82% Buy or better · 39 analysts
Median target
$609.50
+14% · range $350.00–725.00
1 year
+22.8%
from $434.02 · Nov 17
30 days
+6.2%
from $501.95
52-week range
$421.03–558.88
−5% from high · low Nov 19
Avg volume 20D
1.51M
shares / day
Short interest
4.81M
≈1.9% of shares · +12.9%
Days to cover
3.4
at average volume
Insider net
−$17.8M
since Apr 1 · excl. 1 subscriber-only trade
New fund stakes
4
Q3 2026 13F · 3 exits
Reddit crowd
67°
Warm · 2 mentions this week
SecBot read BULLISH 10 reports · 90 days
Balance 0 bearish · 2 bullish · 8 neutral oldest → newest, height = score
Avg score ·High conf. 8/10 ·Next FDA decision date, Nov 30, 2026

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

  • Apr 1 ▼ 1 insider sell $439.3K at $449.17
  • May 1 to May 4 ▼ 2 days of insider sells: $604.0K by 2 insiders, avg $424.73
  • May 12 to May 15 ▼ 2 days of insider sells: $3.8M by 2 insiders, avg $450.57
  • May 29 to Jun 5 ▼ 3 days of insider sells: $2.0M by 2 insiders, avg $448.16
  • Jun 15 to Jun 18 ▼ 2 days of insider sells: $2.3M by 1 insider, avg $452.44
  • Jun 26 to Jul 2 ▼ 3 days of insider sells: $2.3M by 4 insiders, avg $513.12
  • Sep 30 ▲ 4 funds open new positions (13F)
  • Oct 7 ▼ Ro Khanna sold $1,001 - $15,000, last disclosed Nov 9
  • Oct 14 Trial readout: Results Pending: Povetacicept (Phase 2), Completed 63d ago
  • Oct 14 to Oct 19 2 court rulings: VERTEX, INC. v. AVALARA, INC. et al; Vertex Towers, LLC v. Town of Franklin
  • Nov 2 ▲ Vertex reported Q3 2026 total revenue of $3.44 billion, a 12% increa…
  • Nov 6 ▼ 1 insider sell $6.3M at $531.53
  • Nov 12 New insider trade: subscribers see the details Unlock

Signal stack

Where each data set points today.

  • InsidersMIXED

    7 insiders sold $17.8M. Excludes 1 subscriber-only trade.

  • InstitutionsMIXED

    Q3 2026: 52 added (4 new), 35 trimmed or exited. Largest new: Migdal Insurance & Financial Holdings $47.6M, Picton Mahoney Asset Management $14.7M.

  • AnalystsBULLISH

    32 of 39 rate it Buy or better. Median target $609.50 (+14%).

  • Short sellersSTEADY

    Short interest +12.9% to 4.81M shares. 3.4 days to cover, ≈1.9% of shares.

  • TrendUPTREND

    2% above its 50-day average.

  • SocialQUIET

    Crowd 67° (warm) this week from 2 mentions: 2 bullish, 0 bearish. No setup is alerting.

Who's buying

13F· Q3 2026
4
new positions
3
exits
$62.3M
in new stakes · top 2 shown
FundMoveSharesValue
FRANKLIN TEMPLETON INCADD4,461,254$2.4B
Clearbridge Investments, LLCTRIM1,694,414$885.9M
Assenagon Asset Management S.A.ADD1,219,311$637.5M
Neuberger Berman Group LLCADD820,764$429.1M
FIRST TRUST ADVISORS LPDOUBLED701,649$366.8M
MASSACHUSETTS FINANCIAL SERVICES CO /MA/ADD554,575$306.3M
BARCLAYS PLCTRIM524,679$274.3M
BNP PARIBAS FINANCIAL MARKETSADD457,275$239.1M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

39 analysts
Buy 82% rate it Buy or better
Strong Buy12Buy20Hold6Sell0Strong Sell1
12-month targets · 28 analysts

Price is inside the target range. Median implies +14%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Nov 4, 2026Barclays
MAINTAIN
MAINTAINOverweight
Nov 3, 2026JP Morgan
MAINTAIN
MAINTAINOverweight
Nov 3, 2026Goldman Sachs
MAINTAIN
MAINTAINBuy
Nov 3, 2026Morgan Stanley
MAINTAIN
MAINTAINOverweight
Nov 3, 2026Scotiabank
MAINTAIN
MAINTAINSector Outperform
Nov 3, 2026UBS
MAINTAIN
MAINTAINBuy
Congressional trades
VRTX trades disclosed by members of Congress, with disclosure delay.
4 members · 3 buys / 4 sells
DateMemberType AmountDisclosed
Oct 7, 2026 Ro KhannaDHouse Spouse account · Vertex Pharmaceuticals Inc SELL $1K–$15K Nov 5, 2026 +29d
Sep 4, 2026 Ro KhannaDHouse Spouse account · Vertex Pharmaceuticals Inc BUY $1K–$15K Oct 7, 2026 +33d
Aug 26, 2026 David TaylorRHouse Vertex Pharmaceuticals Inc SELL $1K–$15K Sep 5, 2026 +10d
May 27, 2026 Ro KhannaDHouse Spouse account · Vertex Pharmaceuticals Inc SELL $1K–$15K Jun 9, 2026 +13d
Apr 13, 2026 Ro KhannaDHouse Spouse account · Vertex Pharmaceuticals Inc BUY $1K–$15K May 11, 2026 +28d
Mar 27, 2026 Alan ArmstrongRSenate Joint account · Vertex Pharmaceuticals Inc BUY $1K–$15K Jul 21, 2026 +116d
May 3, 2024 Tommy TubervilleRSenate Joint account · Vertex Pharmaceuticals Inc SELL $1K–$15K Aug 5, 2026 +824d

Insider ledger

Form 4
$0
bought · 0 insiders
$17.8M
sold · 7 insiders · excl. 1 subscriber-only trade
DateInsiderTypeValue
Nov 12, 2026🔒 Fresh data, subscribers only
Nov 12, 2026
SELL
Nov 6, 2026
Kewalramani Reshma
CEO & President
Nov 6, 2026
SELL$6.3M
Oct 20, 2026
Brennan Daniel J.
Director
Oct 20, 2026
AWARD$400.3K
Oct 15, 2026
SACHS BRUCE I
Director
Oct 15, 2026
AWARD$47.5K
Oct 15, 2026
Garber Alan M
Director
Oct 15, 2026
AWARD$15.0K
Sep 8, 2026
van Grunsven Jasper
EVP, CP and NPPO
Sep 8, 2026
AWARD8,682 sh
Aug 28, 2026
Ambrose Kristen
SVP & Chief Accounting Officer
Aug 28, 2026
AWARD5,000 sh
Aug 27, 2026
SACHS BRUCE I
Director
Aug 27, 2026
GIFT6,000 sh

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
11 drugs tracked · Drug pipeline →
Upcoming
Recent

Short side

FINRA· Oct 30, 2026
4,811,837
shares short
+12.9%
vs prior settlement
3.4
days to cover
≈1.9%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 16, 2026 SEC
Vertex Pharmaceuticals director Nancy Thornberry filed a Form 144 notice of intent to sell 1,000 shares of common…
144 · Impact 2/10
Nov 16, 2026 SEC
Director Sangeeta Bhatia filed a Form 144 notice of intent to sell 271 shares of Vertex Pharmaceuticals, valued at…
144 · Impact 1/10
Nov 15, 2026 Clinical trial readout
T-90d Trial Readout: VX-670 (Phase 2)
Trial: A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1) Sponsor: Ve
Nov 12, 2026 Insider
🔒 Fresh data, subscribers only
Nov 6, 2026 Insider
Kewalramani Reshma sold 11,866 shares
CEO & President @ $531.53 ($6.3M)
Oct 20, 2026 Insider
Brennan Daniel J. was granted 795 shares
Director @ $503.47 ($400.3K)
Oct 19, 2026 Event
Vertex Towers, LLC v. Town of Franklin
Court ruling (mad), Docket: 1:25-cv-13650
Reddit Mentions per day, 14 days
Crowd this week 67° Warm 2 bullish · 0 bearish
Mentions, 7 days 2 1 in posts · 1 in comments
Recent posts
Recent comments
All social signals and their track records

Washington

Corporate Lobbying

109 lobbying filings and 9 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

SecBot reports

21 filings · 3 bullish · 1 bearish · 17 neutral
All VRTX filing & press-release reports (21)